AstraZeneca Near Decision on Suicide-Linked Drug, CEO Says

Updated on

AstraZeneca Plc will decide in a “few weeks” whether to pursue independently a drug for psoriasis after its partner dropped out of the project, said Pascal Soriot, chief executive officer of the U.K. drug company.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.